BTW, did you know that Thomas Ichim and Dr. Min work(ed)

New Post Public Reply Private Reply Replies (1) Message Board
patientgal

BTW, did you know that Thomas Ichim and Dr. Min work(ed) together at Min labs as far back as 2002? I haven't found yet how much Ichim contributed to the patent. I am assuming a significant amount however:

Discoveries:

My lab keeps its leading position in the areas of tolerant DC, DC-T regulatory interaction, and siRNA silencing DC in heart transplantation research. Our excellence of research are shown by following factors: 1) We are the first to report immune modulation by siRNA modified dendritic cells (Arthritis & Rheumatism 2002, 46 (9): S563; J Immunol 2003, 171:691); 2) We are the first to demonstrate a bi-directional interaction between tolerogenic dendritic cells and T regulatory cells (J Immunol 2003, 170:1034).

Awards received by lab members:

2009

  1. Xiufen Zheng, Genzyme Award, Canadian Transplant Academy Training Day.
  2. Xusheng Zhang, Genzyme Award, Canadian Transplant Academy Training Day.
  3. Xiufen Zheng, Young Investigator Award, American Society of Transplantation.
  4. Xusheng Zhang, Young Investigator Award, American Society of Transplantation.
  5. Xiufen Zheng, Trainee Award, Canadian Society of Transplantation.
  6. Xusheng Zhang, Trainee Award, Canadian Society of Transplantation.

2008

  1. Motohiko Suzuki, FIT Abstract Award, American Academy of Allergy Asthma & Immunology.
  2. Roberto Hernandez-Alejandro, Travel Award, Canadian Society of Transplantation.
  3. Motohiko Suzuki, AAI Trainee Abstract Award, American Association of Immunologist.
  1. Roberto Hernandez-Alejandro, Travel Award to World Transplant Congress, CST.
  2. Motohiko Suzuki, PDF Travel Award, Canadian Society of Immunology.
  3. Motohiko Suzuki, Travel Award, Federation of Clinical Immunology Societies.

2007

  1. Xiufen Zheng, Young Investigator Award, American Society of Transplantation.
  2. Costin Vladau, Travel Award, Federation of Clinical Immunology Societies.
  3. Xiufen Zheng, Travel Award, Federation of Clinical Immunology Societies.
  4. Motohiko Suzuki, Travel Award, Federation of Clinical Immunology Societies.
  5. Xiufen Zheng, CST-Astellas Travel Award, Canadian Society of Transplantation.
  6. Xusheng Zhang, CST-Astellas Travel Award, Canadian Society of Transplantation.
  7. Motohiko Suzuki, Young Investigator Award, American College of Chest Physicians.
  8. Xiufen Zheng, CIHR-STP Award, London Regional Cancer Program.

2006

  1. Xiufen Zheng, Best Abstract Award, Canadian Society of Transplantation.
  2. Mu Li, Travel Award, Annual Meeting of Canadian Society of Transplantation.
  1. Xiufen Zheng, Travel Award, Annual Meeting of Canadian Society of Transplantation.
  2. Mu Li, Young Investigator Award, World Transplant Congress.
  3. Xusheng Zhang (#1), Young Investigator Award, World Transplant Congress.
  4. Xusheng Zhang (#2), Young Investigator Award, World Transplant Congress.
  5. Francis Feng, Young Investigator Award, World Transplant Congress.

2005

  1. Mu Li, Travel Award, Basic Science Symposium of the Transplantation Society.

2004

  1. Allen Qian, Travel Award, International Congress of Immunology.
  2. Mu Li, Travel Award, International Congress of Immunology.
  1. Mu Li, Travel Award, Federation of Clinical Immunology Societies.
  2. Thomas Ichim, Travel Award, International Congress of Immunology.
  3. Thomas Ichim, Travel Award, Federation of Clinical Immunology Societies.

2003

  1. Mu Li, Young Investigator Award, American Society of Transplantation.
  2. Thomas Ichim, Young Investigator Award, American Society of Transplantation

RIVULET MEDIA INC. (RIVU) Stock Research Links

RIVU Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

BiomX Advances Phage-Based Therapy for Diabetic Foot Infections

Updated Category News Views 128

BiomX's Innovative Approach to Diabetic Foot Infections BiomX Inc. (NYSE: PHGE), a pioneering clinical-stage company specializing in natural and engineered phage therapies, has announced exciting developments regarding its novel treatment for diabetic foot infections (DFI). Following supportive feedback from the U.S. Food and Drug Administration (FDA), BiomX is gearing up...

Continue Reading
Moneta's Remote Brain Therapy Beats In-Person Results

Updated Category News Views 35

Innovation in Brain Health Comes via Telephone, Not Apps Sometimes, it's astonishing to see how a simple idea can disrupt an entire industry. Take Moneta Health, for example. Their approach is giving the whole world a wake-up call, quite literally. They're not flaunting fancy new apps or diving deep into virtual reality. Instead, they're harnessing the power of a simple...

Continue Reading
Nextensa Boosts Liquidity with Successful Sale of Shares

Updated Category News Views 167

Nextensa Strengthens Financial Position with Recent Share Sale Nextensa NV/SA, widely recognized as a mixed property investor and developer, has recently achieved a notable financial milestone. The company announced the successful completion of a strategic share sale involving Wereldhave N.V., which has significantly enhanced its liquidity position and set the stage for...

Continue Reading
Taylor Farms Group Unveils Comprehensive Impact Initiatives

Updated Category News Views 140

Taylor Farms Group Unveils Comprehensive Impact Initiatives Highlights Achievements and Continuous Efforts to Nourish Both People and Planet Taylor Farms has recently published its latest Impact Report, showcasing innovative initiatives related to products, processes, people, and community involvement. As a prominent supplier of ready-to-eat salads and healthy fresh...

Continue Reading
Compass, Inc. to Share Annual Results and Insights Soon

Updated Category News Views 130

Compass, Inc. Plans Upcoming Financial Results Announcement Compass, Inc., also known as Compass International Holdings (NYSE: COMP), a leader in global real estate services, is preparing to announce its financial results for the fourth quarter and full-year 2025. This important update will take place after the market closes on February 26, 2026. Investors and...

Continue Reading